EUVIMEDEUVIMED entdecken
Crossref

OnabotulinumtoxinA Injection of the Sphenopalatine Ganglion for Treating Refractory Primary Headache Disorders and Neuropathic Facial Pain: Real World Data

Y Logghe, A Jerjir, N D’hondt, I Smet, N Jerjir, M Devos, J.-P. Van Buyten

Acta Anaesthesiologica Belgica · 29.12.2025 · 76 (Supplement 1) · 117

DOI: 10.56126/76.s.13 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Anaesthesiologica Belgica, online erschienen am 06.03.2026. Verfasst von Y Logghe und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

OnabotulinumtoxinA (BTA) injections targeting the sphenopalatine ganglion (SPG) have been used in patients with refractory chronic cluster headache and idiopathic facial pain, causing a neuronal block. This study evaluated real world data on the effectiveness of BTA injections targeting the SPG in treating refractory primary headache disorders and neuropathic facial pain.

Method

We conducted a retrospective observational cohort study of patients who underwent treatment with a BTA injection of the SPG. Primary outcome focused on the impact on the number of headache attacks and pain intensity on an 11-point Numeric Rating Scale (NRS). As secondary outcomes, quality of life objectified by the Headache Impact Test-6 (HIT-6) questionnaire, patient satisfaction and Patient Global Impression of Change (PGIC) were analyzed.

Results

A total of 43 patients received treatment. In primary headache disorders, NRS declined from 7.7 points baseline to 5.0 (p = 0.017) and attack frequency from 64 attacks per month baseline to 24 based on 17 patients. Analgetic consumption declined in 50% of patients. For facial pain disorders, NRS improved from 6.5 baseline to 4.5 (p = 0.028) based on 10 patients. Better responses on NRS were seen when the needle tip was precisely positioned on the reflection of the lateral wall of the nasal cavity.

Conclusion

This real world study has shown that BTA injections have a favorable effect on pain sensation and quality of life in the treatment of primary headache disorders.

Zitieren

APA

Logghe, Y., Jerjir, A., D’hondt, N., Smet, I., Jerjir, N., Devos, M., & Buyten, J. V. (2025). OnabotulinumtoxinA Injection of the Sphenopalatine Ganglion for Treating Refractory Primary Headache Disorders and Neuropathic Facial Pain: Real World Data. Acta Anaesthesiologica Belgica, 76(Supplement 1), 117. https://doi.org/10.56126/76.s.13

Vancouver

Logghe Y, Jerjir A, D’hondt N, Smet I, Jerjir N, Devos M, et al. OnabotulinumtoxinA Injection of the Sphenopalatine Ganglion for Treating Refractory Primary Headache Disorders and Neuropathic Facial Pain: Real World Data. Acta Anaesthesiologica Belgica. 2025;76(Supplement 1):117. doi:10.56126/76.s.13

BibTeX
@article{Logghe2025,
  author = {Logghe, Y and Jerjir, A and D’hondt, N and Smet, I and Jerjir, N and Devos, M and Buyten, J.-P. Van},
  title = {OnabotulinumtoxinA Injection of the Sphenopalatine Ganglion for Treating Refractory Primary Headache Disorders and Neuropathic Facial Pain: Real World Data},
  journal = {Acta Anaesthesiologica Belgica},
  year = {2025},
  volume = {76},
  number = {Supplement 1},
  pages = {117},
  doi = {10.56126/76.s.13}
}
Kostenlos starten →